Clinical Trials Browser

Waldenstrom Macroglobulinemia × umbralisib × Clear all

NCT03364231 2023-06-23

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

21 enrolled 14 charts

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04635683 2022-09-30

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell